Publications by authors named "Anne Flament"

Claim this Profile
D
Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia.
Daniel Pollyea, Tessa Kerre, Dries Deeren, Yves Beguin, Tara L Lin, Anne Flament

Leukemia· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Proof-of-Concept of a Non-Gene Editing Technology Using miRNA-Based shRNA to Engineer Allogeneic CAR T-Cells.
Caroline Lonez, Jennifer Bolsée, Fanny Huberty, Thuy Nguyen, Céline Jacques-Hespel, Anne Flament

Int J Mol Sci· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.
David A Sallman, Tessa Kerre, Violaine Havelange, Xavier Poiré, Philippe Lewalle, Anne Flament

Lancet Haematol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies.
Lorraine Springuel, Caroline Lonez, Bertrand Alexandre, Eric Van Cutsem, Jean-Pascal H Machiels, Anne Flament

BioDrugs· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?
Xavier Leleu, Francesca Gay, Anne Flament, Kim Allcott, Michel Delforge

Ann Hematol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis